Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial
Abstract Background and Aim To compare the effect of telmisartan and vitamin E on liver histopathology of non‐alcoholic steatohepatitis (NASH) patients. Methods This noninferiority clinical trial was conducted for 1 year. Fatty liver patients with non‐alcoholic fatty liver disease (NAFLD) activity s...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-08-01
|
Series: | JGH Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/jgh3.12315 |
id |
doaj-21c4161488e6400984e6c138e5dea39e |
---|---|
record_format |
Article |
spelling |
doaj-21c4161488e6400984e6c138e5dea39e2021-05-02T14:06:20ZengWileyJGH Open2397-90702020-08-014466366910.1002/jgh3.12315Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trialShahinul Alam0Mushfiqul Abrar1Saiful Islam2Mohammad Kamal3Mohammad J Hasan4Md. Abdullah S Khan5Nooruddin Ahmad6Department of Hepatology Bangabandhu Sheikh Mujib Medical University Dhaka BangladeshDepartment of Hepatology Bangabandhu Sheikh Mujib Medical University Dhaka BangladeshDepartment of Hepatology Bangabandhu Sheikh Mujib Medical University Dhaka BangladeshDepartment of Pathology Bangabandhu Sheikh Mujib Medical University Dhaka BangladeshDepartment of Medicine Pi Research Consultancy Center Dhaka BangladeshDepartment of Medicine Shaheed Sayed Nazrul Islam Medical College Kishoreganj BangladeshDepartment of Hepatology Bangabandhu Sheikh Mujib Medical University Dhaka BangladeshAbstract Background and Aim To compare the effect of telmisartan and vitamin E on liver histopathology of non‐alcoholic steatohepatitis (NASH) patients. Methods This noninferiority clinical trial was conducted for 1 year. Fatty liver patients with non‐alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥ 5 (in liver biopsy) were selected. All methods were in accordance with the Declaration of Helsinki. Patients who received telmisartan and vitamin E were denoted as Group‐T and Group‐E, respectively. Forty patients >18 years old were assigned and divided into two groups (20 in each group). Histological improvements were primary outcome measures. Results Significant improvement in NAS score was noted in both groups (Group E [GE]: 6 ± 0.8 to 4.36 ± 1.4; P = 0.00 and Group T [GT]: 5.6 ± 0.7to 4.9 ± 1.2; P = 0.03). Fibrosis score improved from 1.6 ± 0.5 to 1.5 ± 0.5 in GE and from 1.7 ± 0.9 to 1.5 ± 0.7 in GT (P = 0.67 and 0.42, respectively). Steatosis improved in GE from 2.07 ± 0.6 to 1.14 ± 0.66 (P = 0.00) and in GT from 1.94 ± 0.57 to 1.56 ± 0.8 (P = 0.05). Lobular inflammation improved from 2.0 ± 0.4 to 1.6 ± 0.5 in GE (P = 0.02) and from 1.9 ± 0.3 to 1.8 ± 0.4 in GT (P = 0.58). Ballooning score in GE decreased from 1.9 ± 0.3 to 1.7 ± 0.5 (P = 0.03), and in GT, it reduced from 1.9 ± 0.1 to 1.5 ± 0.5 (P = 0.19). NAS improvement was similar in GE (1.6 ± 1.2) and GT (0.6 ± 1.1; P = 0.07) when controlled for weight reduction. Conclusion Telmisartan was similar to vitamin E in improving the histology of NASH patients.https://doi.org/10.1002/jgh3.12315non‐alcoholic steatohepatitistelmisartanvitamin E |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shahinul Alam Mushfiqul Abrar Saiful Islam Mohammad Kamal Mohammad J Hasan Md. Abdullah S Khan Nooruddin Ahmad |
spellingShingle |
Shahinul Alam Mushfiqul Abrar Saiful Islam Mohammad Kamal Mohammad J Hasan Md. Abdullah S Khan Nooruddin Ahmad Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial JGH Open non‐alcoholic steatohepatitis telmisartan vitamin E |
author_facet |
Shahinul Alam Mushfiqul Abrar Saiful Islam Mohammad Kamal Mohammad J Hasan Md. Abdullah S Khan Nooruddin Ahmad |
author_sort |
Shahinul Alam |
title |
Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial |
title_short |
Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial |
title_full |
Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial |
title_fullStr |
Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial |
title_full_unstemmed |
Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial |
title_sort |
effect of telmisartan and vitamin e on liver histopathology with non‐alcoholic steatohepatitis: a randomized, open‐label, noninferiority trial |
publisher |
Wiley |
series |
JGH Open |
issn |
2397-9070 |
publishDate |
2020-08-01 |
description |
Abstract Background and Aim To compare the effect of telmisartan and vitamin E on liver histopathology of non‐alcoholic steatohepatitis (NASH) patients. Methods This noninferiority clinical trial was conducted for 1 year. Fatty liver patients with non‐alcoholic fatty liver disease (NAFLD) activity score (NAS) ≥ 5 (in liver biopsy) were selected. All methods were in accordance with the Declaration of Helsinki. Patients who received telmisartan and vitamin E were denoted as Group‐T and Group‐E, respectively. Forty patients >18 years old were assigned and divided into two groups (20 in each group). Histological improvements were primary outcome measures. Results Significant improvement in NAS score was noted in both groups (Group E [GE]: 6 ± 0.8 to 4.36 ± 1.4; P = 0.00 and Group T [GT]: 5.6 ± 0.7to 4.9 ± 1.2; P = 0.03). Fibrosis score improved from 1.6 ± 0.5 to 1.5 ± 0.5 in GE and from 1.7 ± 0.9 to 1.5 ± 0.7 in GT (P = 0.67 and 0.42, respectively). Steatosis improved in GE from 2.07 ± 0.6 to 1.14 ± 0.66 (P = 0.00) and in GT from 1.94 ± 0.57 to 1.56 ± 0.8 (P = 0.05). Lobular inflammation improved from 2.0 ± 0.4 to 1.6 ± 0.5 in GE (P = 0.02) and from 1.9 ± 0.3 to 1.8 ± 0.4 in GT (P = 0.58). Ballooning score in GE decreased from 1.9 ± 0.3 to 1.7 ± 0.5 (P = 0.03), and in GT, it reduced from 1.9 ± 0.1 to 1.5 ± 0.5 (P = 0.19). NAS improvement was similar in GE (1.6 ± 1.2) and GT (0.6 ± 1.1; P = 0.07) when controlled for weight reduction. Conclusion Telmisartan was similar to vitamin E in improving the histology of NASH patients. |
topic |
non‐alcoholic steatohepatitis telmisartan vitamin E |
url |
https://doi.org/10.1002/jgh3.12315 |
work_keys_str_mv |
AT shahinulalam effectoftelmisartanandvitamineonliverhistopathologywithnonalcoholicsteatohepatitisarandomizedopenlabelnoninferioritytrial AT mushfiqulabrar effectoftelmisartanandvitamineonliverhistopathologywithnonalcoholicsteatohepatitisarandomizedopenlabelnoninferioritytrial AT saifulislam effectoftelmisartanandvitamineonliverhistopathologywithnonalcoholicsteatohepatitisarandomizedopenlabelnoninferioritytrial AT mohammadkamal effectoftelmisartanandvitamineonliverhistopathologywithnonalcoholicsteatohepatitisarandomizedopenlabelnoninferioritytrial AT mohammadjhasan effectoftelmisartanandvitamineonliverhistopathologywithnonalcoholicsteatohepatitisarandomizedopenlabelnoninferioritytrial AT mdabdullahskhan effectoftelmisartanandvitamineonliverhistopathologywithnonalcoholicsteatohepatitisarandomizedopenlabelnoninferioritytrial AT nooruddinahmad effectoftelmisartanandvitamineonliverhistopathologywithnonalcoholicsteatohepatitisarandomizedopenlabelnoninferioritytrial |
_version_ |
1721490817625882624 |